Klas Telecom demonstrated a strong multipresence at this year's largest-ever U.S. Army Network Integration Evaluation (NIE) 16.1, where the company's products and services supported three...

The 2016 Expo Light Shanghai will be an important theme at the Shanghai Hospitality Design & Engineering Exposition, which will be held at the Shanghai New International Expo Center from March 29...

Value investment firm Brandes Investment Partners, L.P., announced today that Charles Brandes, CFA, will present at the inaugural Asia Value Investor Conference in Hong Kong on December 8, 2015....

Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®)...

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral...

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory...

Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy...

Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA®) significantly...

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition represent a...

Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART) therapy CTL019 in certain types of relapsed or refractory...